반응식
[N:1]1([CH2:7][CH2:8][C:9]([N:11]2[CH2:17][CH2:16][CH2:15][CH2:14][C:13]3[NH:18][CH:19]=[CH:20][C:12]2=3)=[O:10])[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.O=P(Cl)(Cl)Cl.CN([CH:29]=[O:30])C>>[N:1]1([CH2:7][CH2:8][C:9]([N:11]2[CH2:17][CH2:16][CH2:15][CH2:14][C:13]3[NH:18][C:19]([CH:29]=[O:30])=[CH:20][C:12]2=3)=[O:10])[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1참가 물질
4
실험 절차
3-Piperidin-1-yl-1-(5,6,7,8-tetrahydro-1H-pyrrolo[3,2-b]azepin-4-yl)-propan-1-one (225 mg, 0.8 mmol) was formylated with POCl3 (91 μL, 1.2 eq.) and DMF(1 mL) using standard Vilsmierer condition to give 96 mg of 4-(3-piperidin-1-yl-propioyl)-1,4,5,6,7,8-hexahydro-pyrrolo[3,2-b]azepine-2-carbaldehyde as a light yellow solid.
출처 및 근거
- ORD 기록
- ord-6d5f6e63ae44485fae1ef94ce29785e5
- 출처 데이터셋
- uspto-grants-2004_01
- 특허 번호
- US06677368B2
연결된 노트
불러오는 중…